News Alaunos Therapeutics, Inc.

Stocks

TCRT

US98973P3091

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 10:02:16 2026-10-30 EDT			5-day change	1st Jan Change
1.760 ^USD	-6.88%		-37.83%	-41.49%

10-16	Top Premarket Gainers	MT
10-13	Alaunos Therapeutics Enters into Agreement and Plan of Merger with Velaris Therapeutics	CI

All News

Mentions Relevance

10-16	Top Premarket Gainers	MT
10-13	Alaunos Therapeutics Enters into Agreement and Plan of Merger with Velaris Therapeutics	CI
10-13	Alaunos Therapeutics, Inc. Appoints Peter Harwin to Board of Directors	CI
10-13	Top Midday Gainers	MT
10-13	Alaunos Therapeutics, Inc. announced that it expects to receive $349.953008 million in funding	CI
10-13	Alaunos Therapeutics Completes Velaris Acquisition; Shares Surge	MT
10-12	Alaunos Therapeutics, Inc. acquired Velaris Therapeutics, Inc.	CI
10-06	Certain Warrants of Alaunos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-OCT-2026.	CI
10-06	Certain Stock Options of Alaunos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-OCT-2026.	CI
10-06	Certain Common Stock of Alaunos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-OCT-2026.	CI
09-18	Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules	AQ
08-14	Ziopharm: Q2 Earnings Snapshot	AQ
08-14	Alaunos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-29	Alaunos Therapeutics Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment For Body Fat Percentage In 48-Day DIO Mouse Study	CI
06-29	Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study	AQ
05-26	Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies	AQ
05-26	Alaunos Therapeutics Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies	CI
05-18	Alaunos reports preclinical ALN1003 data showing effects on insulin-resistance-related biomarkers and liver histology in diet-induced obesity models	RE
05-18	Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models	AQ
05-18	Alaunos Therapeutics Announces Updated Preclinical Data For ALN1003	CI
05-15	Ziopharm: Q1 Earnings Snapshot	AQ
05-15	Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-31	Ziopharm: Q4 Earnings Snapshot	AQ
03-31	Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	Alaunos Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI